Phase 3 N=12,018 An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children
Influenza
Primary: Number of Subjects With Moderate to Severe RT-PCR Confirmed Influenza. — 90; 242 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=508 A Study of the Safety and Efficacy of MK-1293 Compared to Lantus™ in Participants With Type 1 Diabetes Mellitus (T1DM) (MK-1293-003)
Type 1 Diabetes Mellitus
Primary: Primary: Change From Baseline in Hemoglobin A1c (A1C) at Week 24 — -0.62; -0.66 Percent
Phase 3 N=111 Effect of Fluticasone Furoate Inhalation Powder on the Hypothalamic-pituitary-adrenocortical Axis of Children Aged 5-11 Years With Asthma
Asthma
Primary: Change From Baseline (Expressed as a Ratio) in 0-24 Hour Weighted Mean Serum Cortisol at the End of the Six Week Treatment Period (D 42) in Intention-to-treat (ITT)…
Phase 3 N=302 Achieving Cannabis Cessation-Evaluating N-Acetylcysteine Treatment
Cannabis Dependence
Primary: The Odds of Negative Urine Cannabinoid Tests During Treatment. — 25; 21; 30; 22 cannabis negative urine tests — p=0.985
Phase 3 N=117 Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia
Alopecia
Primary: Number of Participants With Adverse Events (AE) Related to Sexual Function in the Double-blind Treatment Period — 5; 9 Participants — p=0.27
Phase 3 N=1,734 Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease
Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma · Childhood Mixed Cellularity Classical Hodgkin Lymphoma · Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma
Primary: Event-free Survival — 0.89; 0.87; 0.84; 0.87 Probability of survival
Phase 3 N=2,799 A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Primary: Mean Annual Rate of Moderate or Severe COPD Exacerbations — 1.90; 1.74 Exacerbations per participant per year — p==0.025
Phase 3 N=96 Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster
Herpes Zoster
Primary: Number of Vaccine Responders for Anti-gE Antibodies as Determined by ELISA — 74; 26; 26; 22 Participants
Phase 3 N=524 Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men
Hypogonadism · Primary Hypogonadism · Secondary Hypogonadism
Primary: Percentage of Participants Meeting Serum Total Testosterone Average Concentration Criteria for Responder During the 3rd Injection Interval in Part C — 94.0 percentage of…
Phase 3 N=100 A Study of the Efficacy and Safety of Tocilizumab in Adults With Rheumatoid Arthritis.
Rheumatoid Arthritis
Primary: Percentage of Participants With Clinical Disease Activity Index (CDAI) Remission and CDAI Low Disease Activity — 16.5; 34.1 percentage of participants
Phase 3 N=397 A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients
Metastatic Colorectal Cancer
Primary: Progression Free Survival (PFS) Time — 9.2; 7.4 months — p=<0.001
Phase 3 N=764 Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis
Dermatitis, Atopic
Primary: Percentage of Participants Who Achieved Success in Investigator's Static Global Assessment (ISGA) Score at Day 29 — 31.4; 18.0 percentage of participants — p=<0.001
Phase 3 N=48 Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes
Diabetes Mellitus, Type 1
Primary: Maximum Change From Baseline Concentration (Cmax) of Glucagon — 6290.33; 3463.55; 3958.58; 4743.00 picograms per millilitre (pg/mL)
Phase 3 N=1,398 The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
Diabetes · Diabetes Mellitus, Type 1
Primary: Change From Baseline in HbA1c (Glycosylated Haemoglobin) — -0.45; -0.50; -0.54; -0.34 percentage of glycosylated haemoglobin
Phase 3 N=272 Phase III Insulin Add-On Asia Regional Program - ST
Diabetes
Primary: Adjusted Mean Change in HbA1c From Baseline to Week 24 — 0.03; -0.87 percentage of hemoglobin — p=<0.0001